Jekyll and Hyde in the Brain: The Two Faces of p-tau217

By Ram Rao, Ph.D., Principal Research Scientist for Apollo Health

In the search for early detection of Alzheimer’s disease (AD), few biomarkers have generated as much excitement as phosphorylated tau-217 (p-tau217). Measurable through a simple blood test, it has shown remarkable accuracy in identifying AD pathology, often years before symptoms appear. Elevated levels of p-tau217 are strongly associated with amyloid plaques, tau tangles, and an increased risk of cognitive decline. In many ways, it has become a cornerstone in the emerging era of blood-based diagnostics. But findings from a recent study invite us to pause and rethink the role of p-tau217.

A study from the University of Gothenburg has revealed something unexpected: newborns, completely free of neurodegenerative disease, exhibit very high levels of p-tau217, sometimes even higher than those seen in AD patients. These levels are highest at birth and gradually decline over the first months of life, eventually stabilizing at adult levels. This observation challenges a simple interpretation of p-tau217 as merely a marker of brain pathology. How can the same molecule be elevated in both the healthiest brains at the beginning of life and in the diseased brains at its later stages? The answer to this conundrum lies in the context.

Tau phosphorylation plays a fundamental role in brain biology. In early development, it supports neuronal growth, synaptic formation, and the dynamic remodeling of neural circuits. During this phase, elevated p-tau217 appears to reflect a highly active, plastic, and rapidly developing brain. It is not a sign of damage, but of construction and shaping the brain. In contrast, in AD, the same molecular process becomes dysregulated and instead of supporting neuronal function, p-tau begins to aggregate into neurofibrillary tangles, disrupting cellular architecture and impairing communication between neurons. What was once a mechanism of growth now becomes a driver of degeneration. This duality highlights an important principle in biology: the same pathway can be beneficial or harmful depending on regulation, timing, and context.

This phenomenon is not unique to p-tau217. In evolutionary biology, it reflects a concept known as “antagonistic pleiotropy”, the idea that certain genes or molecular pathways (for example, the tumor suppressor p53 and the nutrient-sensing pathway mTOR) provide significant advantages early in life but may become detrimental with aging or under conditions of chronic stress. Another well-known example is Apolipoprotein E4 (ApoE4). While ApoE4 may have conferred evolutionary benefits by enhancing immune responses and improving survival during periods of infection or famine, it is now recognized as the strongest genetic risk factor for late-onset Alzheimer’s disease. p-tau217 appears to belong to this same family of biological “double-edged swords”, molecules that are essential for healthy development but, when dysregulated or chronically activated, can contribute to disease.

For clinicians and researchers, this has important implications. While p-tau217 remains a highly valuable biomarker for AD, offering early detection, differential diagnosis, and a means to track disease progression, it must be interpreted within the broader clinical picture. Elevated levels are not inherently “bad”; rather, they signal a shift in underlying biology that must be understood in context. For patients and the broader public, this finding serves as a reminder that biomarkers are not absolute indicators of disease. They are reflections of biological processes, complex, dynamic, and often multifaceted. From a systems perspective, this is not entirely surprising. Many processes in the body follow similar patterns. Inflammation, for example, is essential for healing in the right context but harmful when chronic. Similarly, mechanisms that drive rapid growth and plasticity early in life can, when dysregulated, contribute to disease later on. p-tau217 may represent another example of this broader biological truth.

Rather than viewing it solely as a marker of decline, we might begin to see p-tau217 as a marker of activity, of change within the brain. In early life, that change reflects growth and development. In later life, it may reflect pathological processes that require attention. Understanding this distinction is critical, not only for interpreting biomarkers, but for designing therapies. If we can learn how the newborn brain tolerates, regulates, and even benefits from high levels of phosphorylated tau, we may uncover new strategies to prevent or slow the progression of AD. What appears at first to be a contradiction may, in fact, be an opportunity, as the newborn brain may hold clues to protecting the aging brain.